Kinase inhibitor-1 manufacturers
- Tarlox-TKI
-
- $148.00 / 1mg
-
2026-04-22
- CAS:2135696-72-7
- Min. Order:
- Purity: 97.03%
- Supply Ability: 10g
- Tarlox-TKI
-
- $148.00 / 1mg
-
2026-04-22
- CAS:2135696-72-7
- Min. Order:
- Purity: 97.03%
- Supply Ability: 10g
|
| | Kinase inhibitor-1 Basic information |
| Product Name: | Kinase inhibitor-1 | | Synonyms: | Kinase inhibitor-1;2-Butenamide, N-[4-[(3-bromo-4-chlorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-4-(dimethylamino)-, (2E)-;Tarlox-TKI;TarloxTKI,Tarlox TKI | | CAS: | 2135696-72-7 | | MF: | C19H18BrClN6O | | MW: | 461.74 | | EINECS: | | | Product Categories: | | | Mol File: | 2135696-72-7.mol |  |
| | Kinase inhibitor-1 Chemical Properties |
| Boiling point | 647.4±55.0 °C(Predicted) | | density | 1.552±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 100 mg/mL (216.57 mM); Water: < 0.1 mg/mL (insoluble) | | form | Solid | | pka | 9.68±0.43(Predicted) | | color | Light yellow to yellow |
| | Kinase inhibitor-1 Usage And Synthesis |
| Uses | Tarlox-TKI, the active metabolite of Tarloxotinib, is an irreversible pan-ErbB TKI (Tarlox-TKI)[1]. | | IC 50 | EGFR | | References | [1] Victoria Jackson-Patel, et al. Hypoxia tumour targeting with Tarloxotinib to improve clinical outcomes for patients with EGFR-dependent malignancies. |
| | Kinase inhibitor-1 Preparation Products And Raw materials |
|